Viracta Therapeutics, Inc.: 10-Q filed 2015-05-05
What Viracta Therapeutics, Inc. reported in its quarterly report filed 2015-05-05 (fiscal Q1 2015): 22 published measures, 45 facts as tagged in accession 0001564590-15-003315.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-05-05
- Fiscal period
- fiscal Q1 2015
- Accession
- 0001564590-15-003315 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Viracta Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 41,302,000 | USD | |
| At 2014-12-31 | 44,246,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 16,793,000 | USD | |
| At 2014-12-31 | 13,802,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 18,784,000 | USD | |
| At 2014-12-31 | 22,186,000 | USD | |
| At 2014-03-31 | 50,354,000 | USD | |
| At 2013-12-31 | 15,121,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -9,128,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | -14,573,000 | USD | 90 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 23,000 | USD | 90 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 854,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 1,995,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | -531,825,000 | USD | |
| At 2014-12-31 | -522,697,000 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 31,000 | USD | |
| At 2014-12-31 | 42,000 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -8,769,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | -8,974,000 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 41,271,000 | USD | |
| At 2014-12-31 | 44,204,000 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 239,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 547,000 | USD | 90 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 15,919,000 | USD | |
| At 2014-12-31 | 27,881,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 2,121,000 | USD | |
| At 2014-12-31 | 3,177,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 9,623,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 10,969,000 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 4,512,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 7,552,000 | USD | 90 |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | -5,000 | USD | |
| At 2014-12-31 | -7,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 1,478,000 | USD | |
| At 2014-12-31 | 1,223,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -9,126,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | -14,566,000 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 5,111,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 3,417,000 | USD | 90 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 11,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 5,000 | USD | 90 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -120,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | -5,052,000 | USD | 90 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -1,056,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 58,000 | USD | 90 |
Inspect the source
- Entity
- Viracta Therapeutics, Inc. / CIK 0001061027
- Captured
- 2026-09-21T17:17:49.171Z
- SEC response SHA-256
46e1f007a1af4059ddd3a1b769d50f0b0415de87e9fba66a6561be1394613e67
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001061027.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))